Pulmonary hypertension (PH) is a complex, multifaceted disorder that requires a comprehensive understanding for effective management. This article aims to provide a concise overview of the fundamentals of PH, including pathophysiology, diagnosis, and treatment strategies.
PH is characterized by increased pressure in the pulmonary arteries. The pathogenesis involves endothelial dysfunction, smooth muscle cell proliferation, and inflammation, leading to vascular remodeling and increased pulmonary vascular resistance. This results in right ventricular overload, which can progress to right heart failure if left untreated.
Diagnosing PH is a multistep process that starts with a high index of suspicion based on symptoms and risk factors. Non-invasive tests such as echocardiography are often the first step, followed by confirmatory right heart catheterization. Diagnostic imaging and laboratory tests are also used to identify the underlying cause and guide treatment.
Treatment of PH is directed at the underlying cause and aimed at reducing pulmonary artery pressure, improving symptoms, and slowing disease progression. Therapeutic options include vasodilators, anticoagulants, diuretics, and oxygen therapy. In severe cases, lung transplantation may be considered.
Management of PH requires a multidisciplinary approach involving cardiologists, pulmonologists, radiologists, and other specialists. This collaborative approach ensures comprehensive patient care and optimizes outcomes.
Understanding the fundamentals of PH is essential for its effective management. With a solid grasp of its pathophysiology, diagnostic strategies, and treatment options, healthcare professionals can significantly improve patient outcomes in this complex disorder.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation